Study Explores Risk of Cancer After Lymphoma Treatment

Article

Among survivors of non-Hodgkin's lymphoma, the risk of developing subsequent treatment-related solid tumors remains elevated for up to 30 years after the initial diagnosis, according to an article first published online March 17 in the Journal of Clinical Oncology.

FRIDAY, March 21 (HealthDay News) -- Among survivors of non-Hodgkin's lymphoma, the risk of developing subsequent treatment-related solid tumors remains elevated for up to 30 years after the initial diagnosis, according to an article first published online March 17 in the Journal of Clinical Oncology.

Kari Hemminki, M.D., Ph.D., of the German Cancer Research Center in Heidelberg, Germany, and colleagues studied data from the Swedish Family-Cancer Database, which included 28,131 patients with non-Hodgkin's lymphoma, in order to investigate the risk of subsequent solid tumors after treatment for the cancer.

Among non-Hodgkin's lymphoma survivors, the standardized incidence ratio (SIR) was 1.65 for solid tumors and 5.36 for lymphohematopoietic malignancies, the investigators found. Among solid tumors, spinal meningioma had the highest incidence rate at 40.8. The SIR decreased as age of diagnosis rose, with highest rates in patients diagnosed in childhood. In addition, among the most common patient age groups, the SIR remained elevated up to 30 years after the diagnosis of non-Hodgkin's lymphoma.

The authors conclude that "therapy-related damage persists at least 30 years and the toll of solid tumors as therapy-related cases is largest 21 to 30 years after diagnosis, which needs to be considered in the medical surveillance schemes of the patients with non-Hodgkin's lymphoma."

AbstractFull Text (subscription or payment may be required)

Copyright © 2008 ScoutNews, LLC. All rights reserved.

Related Videos
James Wallace, MD | Image Credit: Provided by James Wallace, MD
Image Credit: Marcibowers.com
Rob Knight, PhD | Image Credit: Contemporary Pediatrics®
Tammy Brady, MD, PhD | Image credit: Provided by guest
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
Related Content
© 2023 MJH Life Sciences

All rights reserved.